Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
While there are positive aspects, such as reduced R&D expenses and a strategic plan for accelerated approval, significant risks are present. Funding challenges and regulatory uncertainties are major concerns, as the company's plans hinge on securing additional capital. The Q&A reveals management's lack of clarity on critical timelines, further increasing uncertainty. The decrease in cash reserves and increased net loss also contribute to a negative outlook. Without a market cap, we assume mid-cap, leading to a likely stock price decrease of -2% to -8%.
Key Financial Performance
Cash and Cash Equivalents $11 million as of June 30, 2025, compared to $23.3 million as of December 31, 2024. The decrease is due to operational expenses and funding activities.
Research and Development Expenses $2.4 million for Q2 2025, compared to $7.3 million for Q2 2024, a decrease due to the conclusion of patient enrollment and follow-up for the CLOVER-WaM Phase II clinical study and reduced personnel costs.
General and Administrative Expenses $3.6 million for Q2 2025, compared to $6.4 million for Q2 2024, a decrease driven by reduced pre-commercialization efforts and personnel costs.
Other Income and Expense A gain of $0.6 million for Q2 2025, compared to $12.8 million for Q2 2024. The change is primarily due to noncash activities related to warrants.
Net Loss $5.4 million for Q2 2025, compared to $0.9 million for Q2 2024. The increase is attributed to noncash impacts of warrant activity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Iopofosine I-131: Shifted regulatory strategy to submit a new drug application (NDA) under an accelerated approval pathway for treating Waldenstrom's Macroglobulemia (WM). The CLOVER-WaM study will serve as the primary basis for efficacy demonstration. The product has received FDA breakthrough therapy designation and European prime designation.
CLR 125: Phase I trial initiation planned for late 2025 or early 2026 for treating triple-negative breast cancer. Preclinical studies show significant tumor uptake and activity.
CLR 225: Phase I trial planned for pancreatic cancer, contingent on funding. Preclinical studies show excellent biodistribution and activity in solid tumor models.
Global Expansion for Iopofosine I-131: Advancing regulatory strategy in Europe with prime designation and seeking conditional marketing authorization from the EMA. Anticipates EMA response by late Q3 or early Q4 2025.
Funding and Financials: Raised nearly $10 million in recent financings, with $11 million in cash and cash equivalents as of June 30, 2025. Additional $5.8 million raised post-Q2. Cash expected to fund operations into Q2 2026.
Operational Strengthening: Secured a long-term isotope supply agreement to support clinical programs and regulatory milestones.
Regulatory Strategy Shift: Focused on accelerated approval for Iopofosine I-131 in the U.S. and conditional marketing authorization in Europe.
Partnerships: Engaged in discussions with potential regional and global partners to secure non-dilutive capital and expertise.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Strategy Shift: The company has shifted its regulatory strategy to pursue accelerated approval for iopofosine I-131, contingent on sufficient funding and a confirmatory study. This introduces risks related to funding availability and the success of the confirmatory study.
Funding Challenges: The company’s ability to execute its clinical and regulatory plans is heavily dependent on securing additional funding. Current cash reserves are projected to fund operations only until the second quarter of 2026.
Pipeline Development Risks: The initiation of Phase I trials for CLR 125 and CLR 225 is contingent upon sufficient funding. Delays or inability to secure funding could hinder the development of these promising assets.
Regulatory Approval Uncertainty: The success of the accelerated approval pathway for iopofosine I-131 depends on meeting FDA requirements, including a minimum of 12 months of follow-up data and a confirmatory study. Failure to meet these requirements could delay or prevent approval.
Market Entry Risks: The company is pursuing dual regulatory tracks in the U.S. and Europe. Any delays or negative outcomes in these processes could impact the timeline for market entry and revenue generation.
Operational Risks: The company has reduced personnel costs and pre-commercialization efforts, which may impact its ability to execute on strategic objectives effectively.
Competitive Pressures: The company faces competition in the radiopharmaceutical space, which could impact its market share and revenue potential if competitors advance faster or offer superior products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Strategy for Iopofosine I-131: The company plans to submit a New Drug Application (NDA) with the FDA under an accelerated approval pathway for iopofosine I-131 as a treatment for Waldenstrom's Macroglobulinemia (WM), contingent on sufficient funding and a confirmatory study underway. The FDA's breakthrough therapy designation supports this strategy. In Europe, the company is pursuing conditional marketing authorization with the EMA, with a decision expected late Q3 or early Q4 2025.
Partnerships for Iopofosine I-131: Cellectar is in active discussions with potential regional and global partners to secure non-dilutive capital, additional human resources, and expertise to support the development and commercialization of iopofosine I-131.
CLR 125 Development: The company plans to initiate a Phase I trial for CLR 125, targeting triple-negative breast cancer, in late 2025 or early 2026. The trial will focus on determining the recommended Phase II dose and dosing regimen, as well as evaluating safety, tolerability, and initial response.
CLR 225 Development: Cellectar intends to advance CLR 225 into a Phase I study for solid tumors, including pancreatic cancer, contingent on securing sufficient funding. The study will evaluate biodistribution, safety, and tolerability.
Funding and Financial Outlook: The company has raised nearly $10 million in recent financings and expects its cash on hand to fund operations into Q2 2026. Additional funding will be required to support the planned clinical trials and regulatory milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:For the WM program, where do you stand with the EU on the path to approval?
A:The company is in continuing discussions for conditional market authorization with the EMA. For the FDA, they are finalizing a protocol for an accelerated approval confirmatory study and the submission for the NDA. Most of the NDA package is largely completed, and with sufficient capital, they aim to submit later this year or early next year.
Q:For the 125 programs, what are the off-target sites of the greatest concern with that platform?
A:Approximately 25% to 30% of the infused drug is evaluated into the tumor. For off-target tissues, less than 5% of the activity is observed in any single tissue, with the liver being the most common site of accumulation, but still well below concerning levels.
Q:When do you think you would submit this NDA?
A:The company plans to submit the NDA later this year or early next year, depending on funding and preparation of the confirmatory study.
Q:How much has it cost to submit and get iopofosine I-131 approved?
A:The estimated cost for the study is approximately $40 million to $45 million. Around $20 million to $25 million is needed for full enrollment and securing necessary data, with the remainder allocated for follow-up costs. To initiate the study, $10 million to $12 million is required.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear definition of what constitutes 'study initiation' as required by the FDA. They also did not specify the exact timing for the NDA submission, stating it could be later this year or early next year, depending on funding and other factors.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CLOVER WaM
Co
FDA approval
NDA
Phase II
Research Division
TNBC
WaM Phase
WaM study
asset
breakthrough
commitment
confidence
cycle millicurie
designation
dose cycle
effort
failure
financing
funding study
income
iodine
iopofosine treatment
milestone
millicurie dose
minimum month
month follow
noncash
partner
pathway iopofosine
potential iopofosine
progress Cellectar
subset analysis
therapy patient
track
CLRB Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed outlook. While there are positive developments like the promising Phase II data for iopofosine and expanded partnerships, there are significant risks including financial sustainability concerns and regulatory approval uncertainties. The Q&A did not reveal any major concerns but highlighted the reliance on future milestones. The financials show decreased expenses but also a declining cash position. Without a clear market cap, the reaction is uncertain, but the mixed signals suggest a neutral impact on stock price.
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong interest in Phase III trials, potential partnerships, and a clear regulatory strategy for iopofosine I 131. Despite financial losses, the company has reduced expenses and extended its cash runway. The Q&A session reveals optimism about iopofosine's performance and market interest, with some uncertainties around data disclosure. Overall, the positive sentiment from partnerships and regulatory progress outweighs the financial concerns, suggesting a positive stock price movement.
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook. While there are positive developments such as decreased expenses and strong partnership momentum, significant risks persist, including reliance on rare isotopes and funding needs for trials. The Q&A reveals cautious optimism but lacks concrete guidance and pricing details, which may concern investors. Given the balanced nature of positive and negative factors, a neutral stock price reaction is expected.
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Unknown8-14
While there are positive aspects, such as reduced R&D expenses and a strategic plan for accelerated approval, significant risks are present. Funding challenges and regulatory uncertainties are major concerns, as the company's plans hinge on securing additional capital. The Q&A reveals management's lack of clarity on critical timelines, further increasing uncertainty. The decrease in cash reserves and increased net loss also contribute to a negative outlook. Without a market cap, we assume mid-cap, leading to a likely stock price decrease of -2% to -8%.
CLRB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
